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Recombinant adipopnesis inhibitory factor (AGIF) was purified to homogeneity from the conditioned medium of COS-I cells transfected with 
human AGIF cDNA. The amino-terminal sequence analysis of the mature AGIF revealed that AGIF was produced as a precursor consisting of 
199 amino acids and processed into a mature form of 178 amino acids by a cleavage between Ala(- I) and Pro(+ I). The purified AGIF inhibited 
the process ofadipogenesis nmouse 3T3-Ll preadipocytes, indicating that AGIF directly acts on the cells. AGIF acted as an adipogenic antagonist 
not only on the extramedullary cell line 3T3-Ll but also on the mouse bone marrow stroma-derived cell line H-l/A, suggesting that this cytokine 
may regulate adipogenesis in bone marrow. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Adipocytes are among the major constituents of the 
bone marrow stroma in adult mammals [1,2]. In vitro 
studies using long-term bone marrow culture techniques 
have shown that adipocytes and preadipocytes play 
some active roles in stromal cell-associated hema- 
topoiesis, and adipogenesis in the bone marrow stroma 
is believed to affect hematopoiesis in the bone marrow 
microenvironment [1,3-51. However, little is known 
about the regulation of adipogenesis in the bone 
marrow. 
We recently reported the isolation from a human 
bone marrow-derived stromal cell line of a cDNA en- 
coding a novel adipogenesis inhibitory factor (AGIF) 
and identity with interleukin-11 (IL-1 1) [6,7]. Condi- 
tioned medium of COS-1 cells transfected with an 
AGIF expression plasmid suppressed lipoprotein lipase 
(LPL) in 3T3-Ll adipocytes [G]. However, it remains to 
be determined whether suppression of LPL in the cells 
is due to a direct action of AGlF. In this report, we 
describe the purification of AGIF from the transfected 
COS-I -cell conditioned medium, determination of the 
amino-terminal sequence of mature AGIF, and 
biological activities of purified, mature AGIF. 
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2.1. Cot~srrucriorl of AGIF expression plasrnid 
The expression plasmid pSRa-20-2 was constructed by replacing 
the stuffer region of pcDL-SRa296 [8] with the cDNA from pcD-20-2 
[6] that encodes a human AGIF precursor. COS-1 cells were 
transfected with pSRa-20.2according to the DEAE-dextran protocols 
with chloroquine treatment as described [9] and tlte serum-free condi- 
tioned medium was obtained. 
2.2. Pwificariorl of reco/h’rraut AGfF 
Serum-free conditioned medium (7.5 liters) of transfected COS-I 
cells was dialyzed against IO mM borate, pH 9.0, containing I3 mM 
KCI (designated hereafter as ‘borate buffer’). The dialyied sample 
was applied to a CM-Toyopear1650.M column (2.2 X 20.2 cm; ToSOh, 
Tokyo, Japan) and eluted with a O-O.3 M linear gradient of sodium 
cltloride in tltc borate buffer. Fractions were subjected to an LPL 
assay and to Western blotting. The material from the CM-Toyopearl 
column was equilibrated with borate buffer plus 0.5 M sodium 
cltloridc and loaded onto a Superdcs 75pg column (2.6 x GO cm; Phaf- 
macia LKB Biotechnology. Uppsala. Sweden). Marker proteins (Bio- 
Rnd Laboratories, Richmond, CA) were run on the gel filtration col- 
umn under the same conditions. The concentrated material from 
Supcrdex 75pg was equilibrated with the borate buffer plus 20% am- 
monium sulfate, applied to a Phenyl-Toyopearl 6SOM column (2.2 X 
IO cm; Tosoh), and cluted with a 20-O% lincar gradient of am- 
monium sulfate in the borate buffer. Protein concentrations were 
dctcrmincd by use of Bio-Rod Protein Assay Kit (Bio-Rad Labs.) or 
Micro BCA Protein Assay Reagent (Picrcc. Rockford, IL). 
SDS-polyacrylntttidc gel clcctrophorcsis (SDS-PAGE) was pcr- 
forntcd as dcrcribcd by Litcmtttli [IO]. Westcftt blotting was Coll- 
duc~ccl by USC of the Imntun-B!OI Assay Kit (Bio-Rad Labs.). Rabbit 
atttiscra wcrc rniacd against a synthetic AGIF pcptidc tltar cor- 
WS~OII~> to the 27th IO 4lst aminv-acid residues of the human ACID 
precursor dcdwxl from a clotted cUNA [a]. Tltc lg frrrctiw 
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Fig. I . (E) SDS-PAGE and Western blot nnalysis of AGIF protein secreted by transfected COS-I cells. Serum-free culture supcrnatant (160 al) from 
COS-I cells transfected with a negative control plasmid, pcDL-SRcr296 (lane I), or with pSRrr-20-2 (lane 2) was concentrated by trichloroacetic 
acid precipitation and analyzed under reducing conditions on a 12.5% polyacrylamide gel followed by silver staining. The pcDL-SRa296 or 
pSR&ZO-2 transfection supernatant was further subjected to Western blot analysis (lanes 3 and 4, respectively). (b) Analysis of purified, mature 
AGIF by SDS-PAGE. Aliquots of the samples in each purification step were analyzed under reducing conditions on a 12.5% polyacrylamide gel 
followed by silver staining. Samples: culture supernatant of COS-1 cells transfected with pSRa-20-2 (lane 1); materials from CM-Toyopearl (lane 
2), Superdex (lane 3) and Phenyi-Toyopearl (lane 4); and sample buffer only (lane 5). The relative positions of standard proteins (low-molecular- 
weight standards, Bio-Rad Labs.) analyzed in parallel are as indicated (masses in kDa). The positions of mature AGIF are shown by arrows. 
(designated as anti-AGIFpl5) was prepared from the antisera and us- 
ed for Western blotting. 
2.4. Amino aciti sequence analysis 
AGIF-containing fractions from CM-Toyopearl were pooled, elec- 
trophoresed on a 12.5% SDS-polyacrylamide gel, and transferred 
electrophoretically to an lmmobilon membrane (Millipore, Bedford, 
IMA). The area corresponding to the band of AGlF was cut out for 
protein microsequencing. Amino-terminal sequence determination 
was carried out on a gas-phase protein sequencer (model 475A, An- 
plied Biosystems, Foster City, CA). 
2.5. AGIF biological assay 
LPL-suppression activity was determined as described in our 
previous report [6]. To estimate inhibition of adipose conversion in 
3T3-L.1 cells by AGIF, we treated cultures of the cells that had reach- 
ed confluence for 4 days with adipocyte-induction medium (complete 
DMEM [G] containing 5 ~8 of insulin per ml, I MM dexamethasone, 
and 0.5 mM isobutylmcthylxanthine) supplemented with various con- 
centrations of purified AGIF. The medium was then replaced with 
maintenance medium (complete DMEM containing 100 ng of insulin 
per ml) supplemented wil’l AGIF at the same concentrations as above, 
and the cells were cultured for an additional 4 days. Next, the cultures 
were fixed with 5% formaldehyde, and the nuclei and the lipid 
droplets that had accumulated in the cells were then stained with 
hematosylin and Oil red 0, respectively. Photographs were taken, 
and the percentage of adipocyfes was calculated from the number of 
nuclei (stained light-purple) and adipocytes that contained red-stained 
lipid vacuoles. H-I/A cells [Ill were grown at 33°C in Fischer 
medium containing 10% FBS. After the cells had reached confluence, 
the medium was replaced with the adipocyte-induction medium 
(Fischer medium containing 10% FBS and I pM hydrocortisone) sup- 
plemented with several dilutions of conditioned medium of (XX-1 
cells transfectcd with pSRa.20.2, and the cells were cultured for 20 
days. During the culture pericd, the medium was exchanged every 2-5 
days for fresh induction medium containing rhc COS-I conditioned 
medium. Thccells were then fixed and stained, and the percentage of 
adipocytes was determined. 
3. RESULTS 
3.1. Purification of recombinant AGIF 
To characterize the protein encoded by the AGIF 
cDNA, we constructed an expression plasmid, 
pSRcu-20-2, that direct:; a high ievei expression of the 
Table 1 
Purification of recombinant human AGIF 
step Volunlc Total protein Total activity Specific activity Purification Recovery 
(ml) (18) (U X lo-“) (U/lrlrn) (-fold) (%I) 
Conditioned medium 7,500 122,000 600 4.9 x 102 I 100 
CM-foyopcarl 650,M 17.7 920 195 2.1 x IO’ 43 32 
Supcrdcx 75~8 14.8 ’ - 74 IG 2.2 X IO5 45 2.7 
Phcnyl-Toyopcarl 65OM 20.2 19 9 4,9 x 10’ 100 I.5 
One unit (U) of AGIF is dcfincd as the amount of factor rcquircd to induce a 500/o supprcasion of LPL activity in 3T3.LI atlipocytcs cultured in 
ii voiut11c of one ml, 
14 
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Fig. 2. Dose-response of LPL activity in AGIF-treated 3T3-Ll 
adipocytes. Differentiated 3T3-Ll adipocytes were exposed to the in- 
dicated concentrations of purified AGIF for 18 h, after which 
heparin-released LPL activity was determined. LPL activity was ex- 
pressed relative to that in untreated cultures, in which more than 80% 
of the cells had accumulated lipid droplets, and which was defined as 
100%. 
cDNA in COS-1 cells. Western blot analysis by use OF 
anti-AGIFpl5 antibodies confirmed that the protein 
encoded by the cDNA was secreted in the conditioned 
medium of transfected COS-1 cells, and the molecular 
mass of the secreted AGIF was estimated to be 23 kDa 
(Fig. la). 
The purification scheme consisted of the following 
steps: (i) dialysis of conditioned medium against borate 
buffer; (ii) ion-exchange chromatography; (iii) size- 
exclusion chromatography; and (iv) hydrophobic- 
interaction chromatography. In each purification step, 
AGIF was monitored by its LPL-suppression activity in 
3T3-Ll adipocytes and by Western blot analysis. In all 
purification steps, fractions that exhibited LPL- 
suppression activities corresponded to those showing 
AGIF bands in Western blotting. Table I summarizes 
the results of the procedures used to purify recombinant 
AGIF. Size-exclusion chromatography resulted in a 
symmetrical peak of LPL suppression activity in the 
fractions corresponding to apparent molecular masses 
of - 17 kDa, indicating that AGIF may be present as a 
monomer (data not shown). The Phenyl-Toyopearl 
fractions that had exhibited LPL suppression activities 
yielded a single protein peak migrating as a 23-kDa 
band when analyzed by SDS-PAGE under reducing 
conditions (Fig. lb), and this protein was identified as 
AGIF by Western blotting (data not shown). The final 
specific activity was estimated to be 4.9 x 10’ U/mg 
protein. 
3.2. Amino-terminal seqireme of mature AGIF 
We determined the sequence of the first ten amino- 
terminal residues of mature AGIF as NHt-Pro-Gly- 
Pro-Pro-Pro-Gly-Pro-Pro-Arg-Val-. This result in- 
dicates that AGIF is synthesized as a precursor of 199 
amino acids and processed into its mature form by a 
cleavage between the Ala ( - 1) and Pro( + 1) residues, 
which results in a protein of 178 amino acids with a 
predicted molecular weight of 19 144. 
3.3. Biological activity of A GIF 
Purified AGIF suppressed the heparin-releasable 
LPL activity of differentiated 3T3-Ll adipocytes in a 
dose-dependent manner (Fig. 2). This effect was evident 
at concentrations as low as 0.5 ng/ml and was maximal 
at doses of more than 10 ng/mI. This result indicates 
that AGIF directly acts on 3T3-Ll adipocytes. 
Moreover, AGIF inhibited the process of adipogenesis 
in 3T3-Ll cells in a dose-dependent manner (Fig. 3). 
The effective doses were almost the same as in the case 
of LPL suppression in the 3T3-Ll adipocytes. 
We also tested the effect of AGIF on adipogenesis in 
the mouse bone marrow stroma-derived cell line 
H-l/A, which is derived from the adherent cell layer of 
a 14-week-old Dexter bone-marrow culture and thought 
to have originated from adventitial reticular cells in the 
bone marrow [I I]. AGIF inhibited the adipogenic dif- 
ferentiation of H-I/A cells (Fig. 4) as well as it did that 
of 3T3-Ll cells. 
A G I F ( ng/nll 1 
Control AGIF 
Fig. 3. luhibition of sdepopcuic diffcrcnriation of X3-LI cells by AGIF: (tr) photographs (x 150); (h) pcrrcntnpc of udiposc wwcrsion. 3T3mLl 
cells WL’I’U inclurcd to diffcrcntiotc into ttdipocytes in 111~ prcscncc of 111c indicntcd conccntrrttions of purlficd AGIl:, Pltotogr:qrhs dcplcl the results 
ill IIIC prcsctlcc atld nbswrc (illdicolcd ns ctmrnl) of ACillr (12.5 11g/n11). 
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Fig. 4. Inhibition of adipogenesis in the bone marrow stromn-derived 
cell line H-I/A by AGIF. H-l/h cells were cultured for 20 days in 
adipocyte-induction medium supplemented with the indicated final 
dilutions of conditioned medium of COS-I cells transfected with 
pcDLSRa29G (a negative-control plasmid) or pSRo-20-2. Control 
means no addition of COS-I conditioned medium. Open bars and 
closed bars indicate pcDLSRa296 and pSRor-20-2, respectively. 
4. DISCUSSION 
We have purified mature AGIF from medium condi- 
tioned by transfected COS-1 cells and tested its ability 
to act as an antagonist of adipogenesis in H-I/A cells 
and 3T3-Ll cells. Amino-terminal sequence analysis of 
mature AGIF indicates that this protein consists of 178 
amino acids with a predicted molecular weight of 
19 144. The apparent molecular mass (23 kDa) 
estimated by SDS-PAGE analysis (Fig. 1) is larger than 
this calculated molecular mass (19 kDa). Since AGIF 
lacks potential N-linked glycosylation sites and was 
eluted with the fractions corresponding to apparent 
molecular masses of - 17 kDa on a size-exclusion col- 
umn, the smaller mobility of AGIF on SDS- 
polyacrylamide gels might be due to the strongly basic 
characteristics of this protein (calculated pI = 11,3). 
We cannot, however, rule out the possibility of any 
post-translational modification(s). 
AGIF directly suppressed the heparin-releasable LPL 
in 3T3-Ll adipocytes (Fig. 2), but it did not affect the 
activity of the enzyme itself (data not shown). 
Therefore, LPL-suppression by AGIF may be mediated 
by its inhibitory action in any step(s) of the LPL- 
biosynthesis pathway in the cells. AGIF is expressed in 
the bone marrow-derived stromal cell line KM-102 [G], 
and this stroma-derived factor inhibited the process of 
adipogenesis in the bone marrow stroma-derived 
H-l/A preadipocytes (Fig. 4). H-l/A cells produce col- 
ony stimulating factors, and the colony stimulating ac- 
tivity of the cells decreases during their adipocyte 
differentiation [4,5]. Another preadipose cell line, PA6, 
which is thought to originate from bone marrow 
preadipocytes, has a unique capacity to support the 
growth of CFU-S through a cell-to-cell interaction [ 121. 
PA6 cells fail to interact with hematopoietic cells and 
their growth-supporting activity for CFU-S decreases 
when the cells differentiate into adipocytes [3]. We 
therefore hypothesize that AGIF is an inhibitory 
regulator of adipose conversion in bone marrow and 
plays a role in keeping stromal preadipocytes 
hematopoietically active by inhibiting their adipogenic 
differentiation. The AGIF cDNA is now known to be 
identical to that of IL-I 1, a cytokine recently reported 
to be a hematopoietic factor for B cells and 
megakaryocytes [7,13]. AGIF/IL-I1 may be a 
multifunctional factor that acts on both stromal cells 
and hematopoietic progenitor cells in the bone marrow 
microenvironment. 
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